Genetic testing for chronic myeloid leukemia (CML) can tell doctors if someone has leukemia, what type they may have, and whether treatment is working. The tests look for atypical changes in ...

[6] The appearance of new cytogenetic abnormalities in the bone marrow, besides the Philadelphia chromosome, discussed below, is another criterion for accelerated-phase CML. Approximately 20%-40% ...

However, neither the Philadelphia chromosome nor BCR-ABL is pathognomonic of CML, as they are present in other human hematologic malignancies. p210 BCR-ABL is found in 95% of patients with CML ...

Open a VIP account (an enterprise account with priority handling, 24/7 dedicated customer care, unlimited usage/users, help on formatting, standards, rules, regulations, policy compliance, etc., and ...

It is indicated for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) CML in the chronic phase, as well as those who are resistant or intolerant to previous therapies that ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...

Longer-term data for Novartis Scemblix reinforce superior efficacy with favourable safety and tolerability profile in adults with newly diagnosed CML: Basel Tuesday, December 10, ...

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key ...

Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, ...